A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
Open Access
- 10 February 2022
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 38, 17-24
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
- Cancer Research UK
- UCLH Biomedical Research Centre (BRC-1215-20014)
- Janssen Global Services LLC
- Janssen Pharmaceutica
This publication has 30 references indexed in Scilit:
- Risk Group and Death From Prostate CancerJAMA Oncology, 2015
- Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trialResearch and Reports in Urology, 2014
- Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II studyWorld Journal of Urology, 2013
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2013
- Active Surveillance for Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2012
- ARN-509: A Novel Antiandrogen for Prostate Cancer TreatmentCancer Research, 2012
- DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility studyMagnetic Resonance in Medicine, 2011
- Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2010
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006